<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01238770</url>
  </required_header>
  <id_info>
    <org_study_id>3107000</org_study_id>
    <nct_id>NCT01238770</nct_id>
  </id_info>
  <brief_title>Phase I/II Study of Pazopanib and Cyclophosphamide in Patients With Platinum-resistant Recurrent Ovarian Cancer</brief_title>
  <official_title>A Phase I/II Study of Pazopanib (GW786034) and Cyclophosphamide in Patients With Platinum-resistant Recurrent, Pre-treated Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Priv.-Doz. Dr. med. Joachim Rom</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Heidelberg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current trial shall clarify the potential of the multitarget antiangiogenic tyrosinkinase&#xD;
      inhibitor GW 786034 (pazopanib) in combination with oral cyclophosphamide as salvage&#xD;
      treatment in patients with recurrent, pretreated ovarian cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective open-label, non-randomized multicenter phase I/II trial in order&#xD;
      to determine overall response rate of patients with platinum-resistant or refractory&#xD;
      recurrent, pretreated epithelial ovarian cancer.&#xD;
&#xD;
      In order to assure adequate toxicity assessment, a phase-I-trial is proponed. Phase II will&#xD;
      be performed with MTD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of the optimal doses for pazopanib (phase I)</measure>
    <time_frame>42 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall response rate according to RECIST criteria / clinical benefit (stable disease or partial response or complete response) (phase II)</measure>
    <time_frame>12 weeks after start of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression (TTP) according to RECIST criteria</measure>
    <time_frame>7 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>7 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of CA125 tumour response</measure>
    <time_frame>7 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with Adverse Events</measure>
    <time_frame>7 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of quality of life over time as defined by EORTC-QLQ C 30 and Ovar 28 questionnaire</measure>
    <time_frame>7 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Epithelial Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Cyclophosphamid + Pazopanib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cyclophosphamid + Pazopanib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pazopanib</intervention_name>
    <description>Phase I Cyclophosphamid Pazopanib Dose level I 50 mg/day 400 mg/day Dose level II 50 mg/day 600 mg/day Dose level III 50 mg/day 800 mg/day&#xD;
Cyclophosphamide 50 mg daily orally Pazopanib 400, 600 or 800 mg daily orally&#xD;
Phase II:&#xD;
Cyclophosphamide 50 mg daily orally Pazopanib 400, 600 or 800 mg daily orally The dose for the phase II part of the trial will be based on the MTD of phase I.</description>
    <arm_group_label>Cyclophosphamid + Pazopanib</arm_group_label>
    <other_name>Cyclophosphamid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent&#xD;
&#xD;
          2. Female subjects ≥18 years of age&#xD;
&#xD;
          3. Histologically or cytologically confirmed diagnosis of: epithelial ovarian cancer&#xD;
             which is platinum resistant or platinum refractory,cancer of the fallopian tube,&#xD;
             peritoneal cancer&#xD;
&#xD;
          4. Patients must have failed available standard chemotherapy regimen&#xD;
&#xD;
          5. Prior treatment with at least 2 chemotherapy regimens in advanced tumor setting&#xD;
&#xD;
          6. Performance status ECOG 0 - 2&#xD;
&#xD;
          7. Adequate contraception&#xD;
&#xD;
          8. Adequate organ function&#xD;
&#xD;
          9. Measurable disease according to RECIST criteria.&#xD;
&#xD;
         10. Able to swallow and retain oral medication.&#xD;
&#xD;
         11. Life expectancy of at least 12 weeks.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any second malignancy within the last 5 years, with the exception of basal cell or&#xD;
             squamous cell skin cancer or in situ carcinoma of the cervix uteri&#xD;
&#xD;
          2. History or clinical evidence of central nervous system (CNS) metastases or&#xD;
             leptomeningeal carcinomatosis, except for individuals who have previously-treated CNS&#xD;
             metastases, are asymptomatic, and have had no requirement for steroids or anti-seizure&#xD;
             medication for 6 months prior to first dose of study drug.&#xD;
&#xD;
          3. Clinically significant gastrointestinal abnormalities which might interfere with oral&#xD;
             dosing&#xD;
&#xD;
          4. Any unstable or serious concurrent condition (e.g., active infection requiring&#xD;
             systemic therapy).&#xD;
&#xD;
          5. Prolongation of corrected QT interval (QTc) &gt;480 msecs.&#xD;
&#xD;
          6. History of any one or more of the following cardiovascular conditions within the past&#xD;
             6 months:&#xD;
&#xD;
               -  Cardiac angioplasty or stenting&#xD;
&#xD;
               -  Myocardial infarction&#xD;
&#xD;
               -  Unstable angina&#xD;
&#xD;
               -  Symptomatic peripheral vascular disease&#xD;
&#xD;
               -  Coronary artery by-pass graft surgery&#xD;
&#xD;
               -  Class II, III or IV congestive heart failure as defined by the New York Heart&#xD;
                  Association (NYHA)&#xD;
&#xD;
               -  History of cerebrovascular accident, pulmonary embolism or untreated deep venous&#xD;
                  thrombosis (DVT) within the past 6 months&#xD;
&#xD;
          7. Macroscopic hematuria&#xD;
&#xD;
          8. Hemoptysis that is clinically relevant within 4 weeks of first dose of study drug&#xD;
&#xD;
          9. Evidence of active bleeding or bleeding diathesis&#xD;
&#xD;
         10. Known endobronchial lesions or involvement of large pulmonary vessels by tumor&#xD;
&#xD;
         11. Prior major surgery or trauma within 14 days prior to first dose of study drug and/or&#xD;
             presence of any non-healing wound, fracture, or ulcer.&#xD;
&#xD;
         12. Chemotherapy or radiation therapy within 2 weeks prior to the first dose of study&#xD;
             drug.&#xD;
&#xD;
         13. Biological therapy, hormonal therapy or treatment with an investigational agent within&#xD;
             28 days or 5 half-lives&#xD;
&#xD;
         14. Prior antiangiogenic therapy.&#xD;
&#xD;
         15. Is unable or unwilling to discontinue predefined prohibited medications listed in the&#xD;
             protocol for 14 days or five half-lives of a drug (whichever is longer) prior to Visit&#xD;
             1 and for the duration of the study&#xD;
&#xD;
         16. Any ongoing toxicity from prior anti-cancer therapy that is &gt; Grade 1 and/or that is&#xD;
             progressing in severity.&#xD;
&#xD;
         17. Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs&#xD;
             chemically related to pazopanib&#xD;
&#xD;
         18. Psychological, familial, sociological, or geographical conditions that do not permit&#xD;
             compliance with the protocol.&#xD;
&#xD;
         19. Pregnancy&#xD;
&#xD;
         20. More than 3 different chemotherapy regimens in advanced tumor setting&#xD;
&#xD;
         21. Uncontrolled hypertension&#xD;
&#xD;
         22. History of ischemic event (stroke, myocardial infarction, unstable angina, TIA,&#xD;
             symptomatic peripheral vascular disease)&#xD;
&#xD;
         23. History or clinical evidence of thrombo-embolic event&#xD;
&#xD;
         24. History of haemoptysis, cerebral, or clinically significant gastrointestinal&#xD;
             haemorrhage in the past 6 months&#xD;
&#xD;
         25. Active bleeding&#xD;
&#xD;
         26. Signs/Suspicion of intestinal obstruction&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Eichbaum, PD Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medizinische Fakultät Heidelberg Abteilung für Frauenheilkunde und Geburtshilfe</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Marienkrankenhaus Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>22087</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäts-Frauenklinik</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Konstanz Gynäkologie und Geburtshilfe</name>
      <address>
        <city>Konstanz</city>
        <zip>78464</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin der Johannes Gutenberg-Universität Mainz Klinik und Poliklinik für Geburtshilfe und Frauenheilkunde</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsfrauenklinik Tübingen Klinik für Gynäkologie und Geburtshilfe</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>November 10, 2010</study_first_submitted>
  <study_first_submitted_qc>November 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2010</study_first_posted>
  <last_update_submitted>February 8, 2016</last_update_submitted>
  <last_update_submitted_qc>February 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Heidelberg</investigator_affiliation>
    <investigator_full_name>Priv.-Doz. Dr. med. Joachim Rom</investigator_full_name>
    <investigator_title>PD Dr. med</investigator_title>
  </responsible_party>
  <keyword>Ovarian cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

